A forward genetic screen identifies modifiers of rocaglate responsiveness
Files
Date
2021-09-16
Authors
Shen, Leo
Pugsley, Lauren
Cencic, Regina
Wang, HanChen
Robert, Francis
Naineni, Sai Kiran
Sahni, Ananya
Morin, Genevieve
Zhang, Wenhan
Nijnik, Anastasia
Version
Published version
OA Version
Citation
L. Shen, L. Pugsley, R. Cencic, H. Wang, F. Robert, S.K. Naineni, A. Sahni, G. Morin, W. Zhang, A. Nijnik, J.A. Porco, D. Langlais, S. Huang, J. Pelletier. 2021. "A forward genetic screen identifies modifiers of rocaglate responsiveness.." Sci Rep, Volume 11, Issue 1, pp. 18516 - ?. https://doi.org/10.1038/s41598-021-97765-8
Abstract
Rocaglates are a class of eukaryotic translation initiation inhibitors that are being explored as chemotherapeutic agents. They function by targeting eukaryotic initiation factor (eIF) 4A, an RNA helicase critical for recruitment of the 40S ribosome (and associated factors) to mRNA templates. Rocaglates perturb eIF4A activity by imparting a gain-of-function activity to eIF4A and mediating clamping to RNA. To appreciate how rocaglates could best be enabled in the clinic, an understanding of resistance mechanisms is important, as this could inform on strategies to bypass such events as well as identify responsive tumor types. Here, we report on the results of a positive selection, ORFeome screen aimed at identifying cDNAs capable of conferring resistance to rocaglates. Two of the most potent modifiers of rocaglate response identified were the transcription factors FOXP3 and NR1I3, both of which have been implicated in ABCB1 regulation-the gene encoding P-glycoprotein (Pgp). Pgp has previously been implicated in conferring resistance to silvestrol, a naturally occurring rocaglate, and we show here that this extends to additional synthetic rocaglate derivatives. In addition, FOXP3 and NR1I3 impart a multi-drug resistant phenotype that is reversed upon inhibition of Pgp, suggesting a potential therapeutic combination strategy.
Description
License
© The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.